The Interferon Alpha/Beta Receptor 1 pipeline drugs market research report outlays comprehensive information on the Interferon Alpha/Beta Receptor 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Interferon Alpha/Beta Receptor 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Infectious Disease, Oncology, Central Nervous System, and Respiratory which include the indications Coronavirus Disease 2019 (COVID-19), Hepatitis B, Solid Tumor, Metastatic Renal Cell Carcinoma, Multiple Sclerosis, Demyelinating Diseases, Community Acquired Pneumonia, and Pneumonia. It also reviews key players involved in Interferon Alpha/Beta Receptor 1 targeted therapeutics development with respective active and dormant or discontinued products.
The Interferon Alpha/Beta Receptor 1 pipeline targets constitutes close to 56 molecules. Out of which, approximately 53 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 1, 8, 11, 7, 1, 15, and 6 respectively. Similarly, the universities portfolio in Phase 0, Preclinical, and Discovery comprises 1, 1, and 1 molecule.
Interferon Alpha/Beta Receptor 1 overview
Interferon Alpha/Beta Receptor 1 (IFNAR1) is a cell surface protein that binds to type I interferons (IFNs), which are a group of cytokines that play an important role in the antiviral and antitumor immune responses. IFNAR1 is part of the interferon-alpha/beta receptor (IFNAR) complex, which also includes IFNAR2. When IFNs bind to IFNAR, they activate a signaling pathway that leads to the expression of interferon-stimulated genes (ISGs). ISGs have a variety of antiviral and antitumor effects, including inhibiting viral replication, inducing apoptosis, and activating natural killer cells.
For a complete picture of Interferon Alpha/Beta Receptor 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
